Instructions for Reaferon-es (Interferon alfa-2b) lyophilisate 5 ampoules
English product name Reaferon-es
Reaferon-EC
Release Form
Lioph. D/C and Local Approx. 1 million IU: amp. 5 or 10 pcs fl 5 pcs.
Lioph. D/C and Local Approx. 3 million IU: Amp. 5 or 10 pcs, fl 5 pcs.
lioph. d/prigot. r-ra d/injectee and local prim. 5 million IU: amp. 5 or 10 pcs, fl 5 pcs.
liof. d/prigot of r-ra d/injectables and local approx. 500 thousand IU: amp. 5 or 10 pcs, fl 5 pcs.
Description
Lyophilizate for the preparation of a solution for injection and for local use in the form of a powder or a porous mass of white, hygroscopic; during dilution, a colourless transparent or weakly opalescent solution is formed.
1 amp.
human recombinant interferon alpha-2b 5,000,000 IU
Auxiliary substances: albumin, solution for infusions 10% - 4.5 mg, sodium chloride - 8.09 mg, sodium hydrophosphate dodecahydrate - 3.82 mg, sodium dihydrophosphate dihydrate - 0.58 mg.
5000000 ME - ampoules (5) - packages of loop-type cells (1) - cardboard packs.
5000000 IU - ampoules (5) - packages of circuit-type cells (2) - cardboard packs.
5000000 ME - bottles (5) - packages of cell contour (1) - packs of cardboard.
ATC codes
L03AB05 Interferon alfa-2b
Clinical-pharmacological groups / Group affiliation Reaferon-es
Interferon. Antitumor, antiviral and immunomodulating preparation
Active substance Interferon alfa
human recombinant interferon alpha-2b
Pharmaco-therapeutic group
MIBP-Cytokin
Storage Conditions Reaferon-es
The drug should be stored in a place protected from light and inaccessible to children at a temperature not higher than 8 ° C.
Best before date Interferon alfa
The shelf life is 3 years.
Expired drug is not applicable
Pharmacological effect Reaferon-es
The preparation exhibits an antiviral, anti-tumour and immunomodulatory activity.
Human recombinant interferon alpha-2b, which is an active substance in the preparation, is synthesized by bacterial cells of the strain Escherichia coli SG-20050/pIF16. in the genetic apparatus of which the human interferon alpha-2b gene is embedded. It is a protein containing 165 amino acids and is identical in characteristics and properties to human leukocyte interferon alpha-2b
Testimony Reaferon-es
Adults in complex therapy:
acute viral hepatitis B - medium-severe and severe forms at the beginning of the jaundiced period up to the 5th day of jaundice (at a later date, the prescription of the drug is less effective; the drug is not effective in developing hepatic coma and
cholestatic disease course);
acute protracted hepatitis B and C, chronic active hepatitis B and C, chronic hepatitis B with a delta agent, with no signs of cirrhosis and the appearance of cirrhosis;
stage IV kidney cancer, hairy cell leukemia, malignant skin lymphoma (mushroom mycosis, primary reticulosis, reticulossarcomatosis), Kaposi's sarcomas,
basal cell and squamous cell skin cancers, keratoacanthoma, chronic myeloleycosis, histiocytosis from Langerhans cells, subleicemic myelosis,
essential thrombocythemia;
viral conjunctivitis, keratoconjunctivitis, keratitis, keratoiridocyclitis, keratouveitis.
In complex therapy in children from one year:
Acute lymphoblastic leukemia in the remission period after the end of induction chemotherapy (4-5 months of remission);
Respiratory papillomatosis of the larynx, starting from the day after the removal of the papilla.
Method of use, course and dosage Interferon alfa
The preparation is used in/m, n/c, in the center or under the lesion, subconjunctivally and locally. Immediately prior to use, the contents of the ampoule or vial are dissolved in water with a solution of sodium chloride of 0.9% (1 ml - at v/m, n/k and at the source, five ml - at subconjunctival and local administration). The solution of the preparation should be colorless, transparent or with weak opalescence, without sludge and extraneous inclusions. The dissolution time shall be about three
- Nosology Interferon alfa (ICD codes)
- B16
- Acute hepatitis B
- B17.1
- Acute hepatitis C
- B18.0
- Chronic viral hepatitis B with delta agent
- B18.1
- Chronic viral hepatitis B without delta agent
- B18.2
- Chronic viral hepatitis C
- C44
- Other malignant skin formations
- C46
- Sarkoma Kaposi
- C64
- Malignant neoplasm of the kidney, except for the renal lohan
- C84.0
- Mushroom mycosis
- C91.0
- Acute lymphoblastic leukemia [ALL]
- C91.4
- Hairy cell leukemia
- C92.1
- Chronic myeloid leukemia [CML], BCR/ABL-positive
- C96.0
- Multifocal and multisystemic (disseminated) histiocytosis from Langerhans cells [Letterer-Sieve disease]
- C96.5
- Multifocal and unsystemic histiocytosis from Langerhans cells
- C96.6
- Unifocal histiocytosis from Langerhans cells
- D14.1
- Benign laryngeal neoplasm
- D23
- Other benign skin neoplasms
- D47.3
- Essential (hemorrhagic) thrombocythemia
- H10
- Conjunctivitis
- H16
- Keratitis
- H20
- Iridocyclite
